Aamodt R L, Rumble W F, Babcock A K, Foster D M, Henkin R I
Metabolism. 1982 Apr;31(4):326-34. doi: 10.1016/0026-0495(82)90107-x.
The effects of oral zinc on distribution, retention and excretion of orally administered 65Zn were studied in 50 patients with taste and smell dysfunction. The study was conducted in three phases. In the first phase all patients were studied for 21 days after receiving 3-18 microCi of 65Zn as ZnCl2 orally after an overnight fast. In the second phase, started after 21 days and continued for 290 to 440 (mean 336) days, all 50 patients received placebo for ZnSO4. In the third phase 14 patients continued on placebo while 36 received ZnSO4 (100 mg/day Zn++) for 112 to 440 (mean 307) days. Phases two and three were a controlled clinical trial of the effects of zinc on retention of 65Zn tracer. Total body retention and activity in plasma and red cells were measured for all patients throughout the study. Ten of the 36 patients treated with ZnSO4 had additional measurements of 65Zn activity in liver and thigh made using external detectors. Total body retention during the second phase placebo period was not significantly different (p greater than 0.25) for the 36 subjects subsequently treated with ZnSO4 (biological half-time (Tb) 378 +/- 12 days) (mean +/- SEM) and the 14 who were continued on placebo through the third phase of the study (Tb = 384 +/- 8 days). During the third phase patients receiving ZnSO4 showed an accelerated loss of total body 65Zn (Tb = 235 +/- 8 days) which was significantly different (p greater than 0.001) from half-time values during placebo treatment. Accelerated loss of 65Zn from the thigh was apparent immediately while that from the liver began after a mean delay of 107 days. There was no apparent effect of zinc on loss of mean 65Zn activity from red blood cells.
在50例味觉和嗅觉功能障碍患者中研究了口服锌对口服给予的65Zn分布、潴留和排泄的影响。该研究分三个阶段进行。在第一阶段，所有患者在禁食过夜后口服3 - 18微居里的65Zn（以ZnCl2形式），之后研究21天。在第二阶段，于21天后开始，持续290至440（平均336）天，所有50例患者接受硫酸锌的安慰剂。在第三阶段，14例患者继续服用安慰剂，而36例患者接受硫酸锌（100毫克/天锌离子），持续112至440（平均307）天。第二阶段和第三阶段是锌对65Zn示踪剂潴留影响的对照临床试验。在整个研究过程中对所有患者测量全身潴留以及血浆和红细胞中的活性。36例接受硫酸锌治疗的患者中有10例使用外部探测器额外测量了肝脏和大腿中的65Zn活性。在第二阶段安慰剂期，随后接受硫酸锌治疗的36名受试者（生物半衰期（Tb）378±12天）（平均值±标准误）和在研究第三阶段继续服用安慰剂的14名受试者（Tb = 384±8天）的全身潴留无显著差异（p大于0.25）。在第三阶段，接受硫酸锌的患者全身65Zn的丢失加速（Tb = 235±8天），这与安慰剂治疗期间的半衰期值有显著差异（p大于0.001）。大腿中65Zn的丢失立即明显加速，而肝脏中的丢失在平均延迟107天后开始。锌对红细胞中平均65Zn活性的丢失没有明显影响。
